{"id":"https://openalex.org/W1990376387","doi":"https://doi.org/10.5414/cp201847","title":"Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20","display_name":"Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20","publication_year":2013,"publication_date":"2013-04-02","ids":{"openalex":"https://openalex.org/W1990376387","doi":"https://doi.org/10.5414/cp201847","mag":"1990376387","pmid":"https://pubmed.ncbi.nlm.nih.gov/23547849"},"language":"en","primary_location":{"id":"doi:10.5414/cp201847","doi":"https://doi.org/10.5414/cp201847","is_oa":false,"landing_page_url":"https://doi.org/10.5414/cp201847","pdf_url":null,"source":{"id":"https://openalex.org/S166536441","display_name":"International Journal of Clinical Pharmacology and Therapeutics","issn_l":"0946-1965","issn":["0946-1965"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","medline","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310313675","host_organization_name":"Dustri-Verlag","host_organization_lineage":["https://openalex.org/P4310313675"],"host_organization_lineage_names":["Dustri-Verlag"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Int. Journal of Clinical Pharmacology and Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002362734","display_name":"Peter N. Morcos","orcid":"https://orcid.org/0000-0001-9586-4095","observed_orcids":["https://orcid.org/0000-0001-9586-4095"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter N. Morcos","raw_affiliation_strings":["Hoffmann\u2010La Roche, Inc., Nutley, NJ 07110, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hoffmann\u2010La Roche, Inc., Nutley, NJ 07110, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100363169","display_name":"Xiaoping Zhang","orcid":"https://orcid.org/0000-0003-0995-4989","observed_orcids":["https://orcid.org/0000-0003-0995-4989","https://orcid.org/0000-0002-8687-3800"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Xiaoping Zhang","raw_affiliation_strings":["Roche (Switzerland), Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Roche (Switzerland), Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066034815","display_name":"Christine McIntyre","orcid":"https://orcid.org/0009-0000-6504-570X","observed_orcids":["https://orcid.org/0009-0000-6504-570X"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Christine McIntyre","raw_affiliation_strings":["Roche (Switzerland), Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Roche (Switzerland), Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008248783","display_name":"Beate Bittner","orcid":"https://orcid.org/0000-0002-8126-116X","observed_orcids":["https://orcid.org/0000-0002-8126-116X"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Beate Bittner","raw_affiliation_strings":["Roche (Switzerland), Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Roche (Switzerland), Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077975851","display_name":"Lucy Rowell","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lucy Rowell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5109891779","display_name":"Zubair Butt Hussain","orcid":"https://orcid.org/0000-0002-3562-8848","observed_orcids":["https://orcid.org/0000-0002-3562-8848"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zubair Hussain","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.8948,"has_fulltext":false,"cited_by_count":23,"citation_normalized_percentile":{"value":0.73715157,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"51","issue":"07","first_page":"537","last_page":"548"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.5976999998092651,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.5976999998092651,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.22120000422000885,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.04430000111460686,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tocilizumab","display_name":"tocilizumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/rhuph20","display_name":"rHuPH20","score":0.9779999852180481},{"id":"https://openalex.org/keywords/recombinant-human-hyaluronidase","display_name":"recombinant human hyaluronidase","score":0.9789999723434448},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9459999799728394},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":1.0},{"id":"https://openalex.org/keywords/subcutaneous-administration","display_name":"subcutaneous administration","score":0.7929999828338623},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.6740000247955322},{"id":"https://openalex.org/keywords/drug-exposure","display_name":"drug exposure","score":0.3709999918937683},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.5090000033378601},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7879999876022339},{"id":"https://openalex.org/keywords/il-6-receptor-inhibitor","display_name":"IL-6 receptor inhibitor","score":0.5820000171661377},{"id":"https://openalex.org/keywords/single-ascending-dose","display_name":"single ascending dose","score":0.6029999852180481},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.7369999885559082},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.45899999141693115},{"id":"https://openalex.org/keywords/injection-site-reactions","display_name":"injection site reactions","score":0.367000013589859}],"concepts":[{"id":"https://openalex.org/C2777178219","wikidata":"https://www.wikidata.org/wiki/Q425154","display_name":"Tocilizumab","level":3,"score":0.9245924949645996},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.8291994333267212},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.695112943649292},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.657687246799469},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6494179368019104},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5934965014457703},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5401358604431152},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.5378190279006958},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.47597306966781616},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.35207802057266235},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3441396653652191},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.11896634101867676}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002097","descriptor_name":"C-Reactive Protein","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006821","descriptor_name":"Hyaluronoglucosaminidase","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D006821","descriptor_name":"Hyaluronoglucosaminidase","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008657","descriptor_name":"Metabolic Clearance Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015233","descriptor_name":"Models, Statistical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D015850","descriptor_name":"Interleukin-6","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D018836","descriptor_name":"Inflammation Mediators","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019947","descriptor_name":"Receptors, Interleukin-6","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.5414/cp201847","doi":"https://doi.org/10.5414/cp201847","is_oa":false,"landing_page_url":"https://doi.org/10.5414/cp201847","pdf_url":null,"source":{"id":"https://openalex.org/S166536441","display_name":"International Journal of Clinical Pharmacology and Therapeutics","issn_l":"0946-1965","issn":["0946-1965"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","medline","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310313675","host_organization_name":"Dustri-Verlag","host_organization_lineage":["https://openalex.org/P4310313675"],"host_organization_lineage_names":["Dustri-Verlag"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Int. Journal of Clinical Pharmacology and Therapeutics","raw_type":"journal-article"},{"id":"pmid:23547849","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23547849","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International journal of clinical pharmacology and therapeutics","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2011709831","https://openalex.org/W2011138201","https://openalex.org/W1490012941","https://openalex.org/W1517879760","https://openalex.org/W4399484120","https://openalex.org/W2899503796","https://openalex.org/W1983574067","https://openalex.org/W3045799095","https://openalex.org/W2510563610","https://openalex.org/W4378347895"],"abstract_inverted_index":{"OBJECTIVES:":[0],"To":[1],"investigate":[2],"the":[3,70,101],"safety,":[4],"tolerability,":[5],"pharmacokinetics":[6],"(PK),":[7],"and":[8,14,50,57,79,85,96,127,147,163,170,180,210,232,244,251,254],"pharmacodynamics":[9],"(PD)":[10],"of":[11,93,111,189,280],"tocilizumab":[12,37,41,112,118,121,124,128,134,190,217,227,267,271,281],"with":[13,60,84,113,193,253,261,270,282],"without":[15,86,115,255],"rHuPH20":[16,87,194,262,283],"(a":[17],"recombinant":[18],"human":[19],"hyaluronidase)":[20],"in":[21,196,220,238,259,264],"healthy":[22],"volunteers.":[23],"METHODS:":[24],"This":[25],"was":[26,88,284],"an":[27],"open-label,":[28],"single":[29,109],"ascending":[30],"dose":[31,110,224,249],"study.":[32,102],"Subjects":[33],"were":[34,53,58,98,137,247,276],"assigned":[35],"to":[36,76],"162":[38,119,122,191],"mg":[39,46,192],"or":[40,44,114],"162,":[42],"324,":[43],"648":[45,129],"plus":[47],"rHuPH20.":[48,116,256],"PK":[49,135],"PD":[51,274],"samples":[52],"collected":[54],"after":[55],"dosing":[56],"estimated":[59,89],"non-compartmental":[61],"methods.":[62],"Geometric":[63],"mean":[64,131],"ratio":[65],"(GMR)":[66],"for":[67,152,168,185,204,226],"area":[68],"under":[69],"plasma":[71],"concentration-time":[72],"curve":[73],"from":[74,223],"zero":[75],"infinity":[77],"(AUC0-\u221e)":[78],"(maximum":[80],"serum":[81],"concentration)":[82],"Cmax":[83,228],"using":[90],"one-way":[91],"analysis":[92],"variance.":[94],"Safety":[95],"tolerability":[97],"monitored":[99],"throughout":[100],"RESULTS:":[103],"48":[104],"subjects":[105],"(12/cohort)":[106],"received":[107],"a":[108],"For":[117],"mg,":[120],"mg/rHuPH20,":[123,126,130],"324":[125],"\u00b1":[132,139,142,145,149,155,158,161,165,172,175,178,182],"SD":[133],"parameters":[136],"2,510":[138],"1,060,":[140],"2,860":[141],"468,":[143],"10,800":[144],"3,220,":[146],"29,900":[148],"5,280":[150],"\u03bcg\u00d7h/ml":[151],"AUC0-\u221e;":[153],"11.5":[154],"3.7,":[156],"16.2":[157],"2.8,":[159],"43.8":[160],"12.4,":[162],"77.8":[164],"14.5":[166],"\u03bcg/ml":[167],"Cmax;":[169],"89.1":[171],"41.1,":[173],"54.0":[174],"19.5,":[176],"66.0":[177],"26.8,":[179],"86.1":[181],"50.6":[183],"h":[184],"tmax,":[186],"respectively.":[187],"Coadministration":[188],"resulted":[195,219,263],"slightly":[197,265],"increased":[198,266],"exposure:":[199],"GMR":[200],"(90%":[201],"confidence":[202],"interval)":[203],"AUC0-\u221e,":[205],"1.20":[206],"(1.00":[207],"-":[208,214],"1.44)":[209],"Cmax,":[211],"1.45":[212],"(1.24":[213],"1.70).":[215],"Increasing":[216],"doses":[218],"significant":[221],"deviation":[222],"proportionality":[225],"(p":[229,234],"=":[230],"0.0057)":[231],"AUC0-\u221e":[233],"<":[235],"0.0001).":[236],"Changes":[237],"interleukin-6,":[239],"soluble":[240],"interleukin-":[241],"6":[242],"receptor,":[243],"C-reactive":[245],"protein":[246],"also":[248],"dependent":[250],"similar":[252],"CONCLUSIONS:":[257],"Tocilizumab":[258],"combination":[260],"exposure":[268],"compared":[269],"alone,":[272],"whereas":[273],"markers":[275],"comparable.":[277],"Subcutaneous":[278],"administration":[279],"well":[285],"tolerated.":[286]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":4},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":3},{"year":2015,"cited_by_count":3},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}